"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
(Generic versions may still be available.)
Information for Patients: Patients should use NASAREL at regular intervals since its effectiveness depends on its regular use. Patients should take the medication as directed and should not exceed the prescribed dose. A decrease in symptoms can be expected to occur within a few days of initiating therapy in allergic rhinitis patients. Patients should contact their physician if the condition worsens, if sneezing or nasal irritation occurs, or if symptoms do not improve by 3 weeks.
Persons taking immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.
For proper use of this unit and to attain maximum improvement, the patient should read and follow the accompanying Patient Instructions carefully.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Nasalide Information
- Nasalide Drug Interactions Center: flunisolide nasl
- Nasalide Side Effects Center
- Nasalide Overview including Precautions
- Nasalide FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Allergies & Asthma
Improve treatments & prevent attacks.